Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−95 JPY
−1.94 B JPY
63.04 M JPY
23.34 M
About ONCOLYS BIOPHARMA INC
Sector
Industry
Headquarters
Tokyo
Website
Founded
2004
ISIN
JP3202170001
FIGI
BBG005HVWTC9
Oncolys BioPharma, Inc. engages in the research and development of cancer treatment therapy and diagnostics which include early detection, loco-regional therapy, prognostic test, and systemic treatments. It operates through the Pharmaceutical and Diagnostics segments. The Pharmaceutical segment deals with the research, development, manufacture, and sale of pharmaceutical products. The Diagnostics segment engages in the research, development, manufacture, and sale of test agents and equipment as well as the provision of testing services. The company was founded by Yasuo Urata on March 18, 2004 and is headquartered in Tokyo, Japan.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of 4588 is 506 JPY — it has decreased by −16.50% in the past 24 hours. Watch ONCOLYS BIOPHARMA INC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on TSE exchange ONCOLYS BIOPHARMA INC stocks are traded under the ticker 4588.
4588 stock has fallen by −21.67% compared to the previous week, the month change is a −26.88% fall, over the last year ONCOLYS BIOPHARMA INC has showed a −7.33% decrease.
4588 reached its all-time high on Mar 14, 2019 with the price of 4,410 JPY, and its all-time low was 401 JPY and was reached on Feb 12, 2016. View more price dynamics on 4588 chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
4588 stock is 19.76% volatile and has beta coefficient of 1.30. Track ONCOLYS BIOPHARMA INC stock price on the chart and check out the list of the most volatile stocks — is ONCOLYS BIOPHARMA INC there?
Today ONCOLYS BIOPHARMA INC has the market capitalization of 12.58 B, it has decreased by −8.04% over the last week.
Yes, you can track ONCOLYS BIOPHARMA INC financials in yearly and quarterly reports right on TradingView.
ONCOLYS BIOPHARMA INC is going to release the next earnings report on Feb 7, 2025. Keep track of upcoming events with our Earnings Calendar.
4588 net income for the last quarter is −491.82 M JPY, while the quarter before that showed −390.63 M JPY of net income which accounts for −25.90% change. Track more ONCOLYS BIOPHARMA INC financial stats to get the full picture.
No, 4588 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 21, 2024, the company has 34.00 employees. See our rating of the largest employees — is ONCOLYS BIOPHARMA INC on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. ONCOLYS BIOPHARMA INC EBITDA is −1.85 B JPY, and current EBITDA margin is −3.06 K%. See more stats in ONCOLYS BIOPHARMA INC financial statements.
Like other stocks, 4588 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ONCOLYS BIOPHARMA INC stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So ONCOLYS BIOPHARMA INC technincal analysis shows the strong sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating ONCOLYS BIOPHARMA INC stock shows the strong sell signal. See more of ONCOLYS BIOPHARMA INC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.